Company Badge
USPTO Data Jan 1 1976 - Oct 20 2026
5 Patents
#2,721 in Tokyo
#6,654 in Japan
Oncolys Biopharma, Inc.
Forward Citations = 11
20 inventors:
Oncolys Biopharma, Inc.
% Expired Patents = 80.0
EPO Patents = 7
Trademarks = 1
Forward Citations = 11
Loading Chart...
Loading Chart...
20 inventors (with patents filed for the assignee):
Toshiyuki Sakai (2 out of 11 patents)
Noriaki Tanaka (2 out of 14 patents)
Toshiyoshi Fujiwara (2 out of 9 patents)
4. Satoru Kyo (2 out of 2 patents)
5. Katsuyuki Nagai (1 out of 21 patents)
6. Hiroyuki Mizuguchi (1 out of 8 patents)
7. Takao Hayakawa (1 out of 3 patents)
8. Shinya Kiguchi (1 out of 2 patents)
9. Hiroya Koyama (1 out of 4 patents)
10. William Ewan Hume (1 out of 1 patent)
11. Satoshi Tsujimoto (1 out of 1 patent)
12. Yoshiko Shirakiya (1 out of 1 patent)
13. Takeshi Kawashima (1 out of 1 patent)
14. Shigehide Kagaya (1 out of 1 patent)
15. Takamichi Sato (1 out of 3 patents)
5 patents:
Company Overview
Oncolys Biopharma, Inc. is a biotechnology company focused on developing innovative cancer treatments. They specialize in oncolytic virus therapy, using viruses to target and destroy cancer cells. Their mission is to improve the lives of cancer patients through cutting-edge research and development.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncolys Biopharma, Inc.. Retrieved from https://idiyas.com/company/oncolys-biopharma
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
7 patents (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]